US Asset Strategy, Obesity and Related Conditions, Director
Amgen
Summary
The Director, US Asset Strategy will lead US commercial strategy for future indications across the obesity and related conditions portfolio, beginning with the next anticipated indication. This leader will translate Global strategy into actionable US plans, bringing deep knowledge of the US market and practical commercialization experience to launch preparation.
Job description
Key Responsibilities
Lead US Indication Strategy
- Develop and lead US commercial strategy for future indications, translating Global strategy into actionable US plans that reflect market dynamics, customer needs, and commercial priorities.
- Assess US treatment pathways, patient populations, HCP segments, competitive dynamics, and unmet needs to inform indication positioning and priorities.
- Partner closely with Global Marketing to understand evolving evidence, strategic assumptions, and development milestones and translate their implications for US commercialization.
- Collaborate with Insights & Analytics to shape US market research, interpret customer insights, and refine indication strategy.
- Identify US opportunities and challenges early and provide clear recommendations to commercial leadership.
Lead US Commercial Planning and Readiness
- Lead US commercial planning for future indications from early preparation through regulatory milestones, approval, and launch readiness.
- Translate indication strategy into US commercialization requirements, milestones, and functional priorities.
- Partner with Medical Affairs, Market Access, HCP Marketing, Consumer Marketing, Sales, Analytics, Regulatory, Corporate Affairs, and Operations to integrate indication needs into established plans.
- Anticipate the US commercial implications of clinical data, regulatory decisions, competitor developments, and changing market conditions.
- Identify gaps, dependencies, and execution risks and work with functional owners and Launch Integration to address them.
- Support development of indication specific US readiness criteria and performance measures with the core launch team.
Integrate Future Indications into the US Business
- Assess how additional indications may change US customer segments, treatment pathways, targeting, promotional priorities, and commercial capabilities.
- Partner with established US brand teams to leverage existing strategies, customer engagement platforms, and infrastructure where appropriate.
- Ensure future indication plans complement the approved indication and support a coordinated experience for HCPs and patients.
- Serve as the primary US commercial strategy contact for future indications, connecting Global planning with US execution requirements.
Lead Team and Cross Functional Collaboration
- Lead, coach, and develop a direct report, establishing clear priorities, accountability, and high standards for delivery.
- Build trusted relationships across US and Global leadership teams and influence decisions without direct authority over partner functions.
- Synthesize clinical, competitive, customer, and commercial information into concise recommendations and decision materials for leadership.
- Balance strategic thinking with hands on execution and foster a culture of collaboration, ownership, and results.
Requirements
- Doctorate degree and 4 years of Marketing experience OR Master's degree and 7 years of Marketing experience OR Bachelor's degree and 9 years of Marketing experience
- Significant US pharmaceutical or biotechnology commercialization experience
- Demonstrated success translating Global asset or brand strategy into effective US plans
- Proven experience preparing new products or indications for launch, including planning through regulatory approval and commercial execution
- Strong understanding of Global and US commercial organizations, with deep knowledge of US market dynamics, customer needs, and commercialization requirements
- Demonstrated ability to interpret clinical evidence, treatment paradigms, competitive intelligence, and research to inform US commercial strategy
- Experience developing US indication strategies, including market assessment, customer segmentation, positioning, and launch planning
- Strong understanding of US healthcare delivery, market access, HCP engagement, and patient marketing
- Proven ability to lead and develop people and drive accountability for results
- Demonstrated success influencing senior leaders and coordinating cross functional teams in highly matrixed organizations
- Excellent executive communication and presentation skills
- Track record of delivering results in fast paced, high visibility environments while balancing strategy with detailed execution
Benefits
- Retirement & Savings Plan
- Medical, Dental & Vision
- Life & Disability Insurance
- Flexible Spending Accounts
- Annual Bonus Program
- Stock-Based Long-Term Incentives
- Paid Time Off
- Flexible Work Models
Company overview
Amgen Inc. is a leading American multinational biopharmaceutical company headquartered in Thousand Oaks, California, founded in 1980. As one of the world's largest independent biotechnology companies, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on six key therapeutic areas: inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen's portfolio includes blockbuster drugs such as Enbrel for autoimmune diseases, Prolia and XGEVA for osteoporosis, Repatha for cholesterol management, Otezla for psoriasis, and Neulasta for chemotherapy-induced neutropenia. With approximately 28,000 employees worldwide, Amgen operates as a component of both the Dow Jones Industrial Average and Nasdaq-100 indices. The company maintains a robust research and development pipeline with numerous clinical programs across various stages, leveraging cutting-edge biotechnology and human genetic data to address some of the world's most challenging diseases. Amgen's manufacturing capabilities span multiple global locations, and it distributes products through pharmaceutical wholesale distributors and direct-to-consumer channels.